AVL-3288

DRUG3 trials

Sponsors

University of Colorado, Denver, New York State Psychiatric Institute, University of Maryland, Baltimore

Conditions

Cognitive ChangeSchizoaffective DisorderSchizophrenia

Phase 1

Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects

TerminatedNCT01851603

University of Colorado, DenverSchizophrenia

Start: 2013-06-30End: 2016-08-31Updated: 2016-12-30

Clinical Trial of AVL-3288 in Schizophrenia Patients

CompletedNCT02978599

New York State Psychiatric InstituteSchizoaffective Disorder, Schizophrenia

Start: 2016-11-30End: 2018-11-02Updated: 2019-01-22

The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine

WithdrawnNCT03281694

University of Maryland, BaltimoreCognitive Change

Start: 2018-05-31End: 2019-02-28Updated: 2024-11-06